Drug Trial Radar · NCT07775287
Study of Petosemtamab Plus Chemotherapy Versus Cetuximab or Bevacizumab Plus Chemotherapy in RAS and BRAF Wild Type, Recurrent, Unresectable or Metastatic Colorectal Cancer (LiGeR-CRC2)
Last checked: Nov 19, 2026Latest source record: Nov 16, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Recruiting
Enrollment
600
Planned (sponsor's estimate)
Start
Oct 7, 2026
Primary completion
Mar 30, 2029
Study completion Jan 31, 2030
Sponsor
- Lead sponsor
- GenmabIndustry
- Sponsor type
- Industry
- First posted
- Aug 20, 2026
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The purpose of this trial is to evaluate how well petosemtamab in combination with chemotherapy works against colorectal cancer that has recurred after previous treatment and that cannot be safely removed by surgery or has spread to other parts of the body. Participants will receive either petosemtamab + doctor's choice of chemotherapy (mFOLFOX6 or FOLFIRI) or doctor's choice of standard-of-care (SOC) cetuximab or bevacizumab + chemotherapy (mFOLFOX6 or FOLFIRI). No participants will be given placebo. The treatment duration will be different for every participant. If a participant's cancer stays the same or gets better, and there are not any serious problems, participants can keep getting study treatment for as long as the study is open. Participants will be asked to attend 2 visits at the study clinic for each cycle (duration of cycle is 4 weeks). During visits, there will be various tests (such as blood draws) and procedures (such as imaging) to monitor whether the study treatment is safe and effective. The overall study duration (including screening, treatment, and follow-up) will be different for every participant.
Conditions
- Colorectal Cancer
Interventions
PetosemtamabDrug
Intravenous (IV) infusion.
CetuximabDrug
IV infusion.
BevacizumabDrug
IV infusion.
5-FUDrug
IV infusion.
Leucovorin (Calcium Folinate)Drug
IV infusion.
OxaliplatinDrug
IV infusion.
IrinotecanDrug
IV infusion.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Progression-free Survival (PFS) per Response Evaluation Criteria in Solid Tumors (RECIST) v1.1 as Assessed by Blinded Independent Central Review (BICR)Time frame: Up to approximately 2.5 years
- Objective Response Rate (ORR) per RECIST v1.1 as Assessed by BICRTime frame: Up to approximately 2.5 years
Locations
7 sites in 2 countries. Site status is shown where the registry gives one.
Genesis Cancer Center Hot Springs National Park
Hot Springs, Arkansas · Recruiting
Valkyrie Clinical Trials - Los Angeles
Los Angeles, California · Recruiting
Moffitt Cancer Center
Tampa, Florida · Recruiting
Low Country Cancer Care Associates_Savannah_2
Savannah, Georgia · Recruiting
New York Cancer and Blood Specialists - Babylon Medical Oncology
Babylon, New York · Recruiting
Vista Oncology - West Olympia_Olympia_2
Olympia, Washington · Recruiting
PanOncology
Manati, Puerto Rico · Recruiting
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.